Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Oncotarget | Site of analysis matters – Ongoing complete response to Nivolumab in a patient with HIV/HPV related metastatic anal cancer and MLH1 mutation

News

September 29, 2022
PRESS RELEASE: A new Oncotarget research paper was published, entitled, “Site of analysis matters - Ongoing complete response to Nivolumab in a patient with HIV/HPV related metastatic anal cancer and MLH1 mutation.” continue reading »

How High Altitudes Influence HIF-1, Gastric Cancer & Patient Survival

Oncotarget

September 27, 2022
In a new study, researchers evaluated the high altitude in Ecuador and how it may influence HIF-1 expression and the survival of Ecuadorian patients with gastric cancer. continue reading »

Protein-Based Risk Model Predicts Esophageal Cancer Recurrence

Oncotarget

September 23, 2022
Researchers developed a multi-protein expression-based risk model to predict recurrence-free survival for ESCC patients. continue reading »

Oncotarget | Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy

News

September 20, 2022
PRESS RELEASE: A new Oncotarget research paper was published, entitled, “Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy.” continue reading »

Behind the Study: Inhibition of Resistant Triple-negative Breast Cancer Cells

Oncotarget

September 19, 2022
Dr. Balraj Singh from the University of Texas MD Anderson Cancer Center, describes a recent research paper he co-authored that was published by Oncotarget, entitled, “Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine.” continue reading »